SPRY
ARS Pharmaceuticals, Inc.
$7.17
-0.13
(-1.78%)
Mkt Cap
711.96M
Volume
1,575,230
52W Range
6.66-18.9
Sector
Healthcare
Beta
0.80
EPS (TTM)
-2.01
P/E Ratio
-6.70
Revenue (TTM)
98.99M
Rev Growth (5Y)
+36.4%
EPS Growth (5Y)
N/A
Company Description
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 84.28M | 89.15M | 30,000 | 1.32M | 5.51M | 17.84M | 0 | 0 |
| Net Income | (171.30M) | 8.00M | (54.37M) | (34.68M) | (20.24M) | (1.06M) | (23.97M) | (17.58M) |
| EPS | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 | -0.03 | -0.72 | -0.53 |
| Free Cash Flow | (171.21M) | 12.98M | (59.44M) | (40.28M) | (17.62M) | 8.15M | (18.99M) | (17.32M) |
| FCF / Share | -1.74 | 0.13 | -0.62 | -1.01 | -0.61 | 0.23 | -0.57 | -0.52 |
| Operating CF | (170.87M) | 13.55M | (59.27M) | (40.08M) | (17.56M) | 9.07M | (18.90M) | (16.88M) |
| Total Assets | 327.65M | 351.15M | 233.19M | 281.44M | 61.45M | 26.41M | 15.65M | 27.55M |
| Total Debt | 96.96M | 42,000 | 274,000 | 481,000 | 9.03M | 10.02M | 15.62M | 7.73M |
| Cash & Equiv | 41.32M | 50.82M | 70.97M | 210.52M | 60.06M | 24.52M | 9.98M | 20.16M |
| Book Value | 114.26M | 256.80M | 230.76M | 272.89M | (31.27M) | (14.05M) | (5.60M) | 18.20M |
| Return on Equity | -1.50 | 0.03 | -0.24 | -0.13 | N/A | N/A | N/A | -0.97 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.68M | 28.09M | 32.50M | 15.72M | 7.97M | 86.58M | 2.07M | 500,000 | 0 | 0 | 0 | 10,000 |
| Net Income | (60.62M) | (41.32M) | (51.15M) | (44.88M) | (33.94M) | 49.93M | (19.13M) | (12.52M) | (10.29M) | (7.17M) | (14.87M) | (17.37M) |
| EPS | -0.61 | -0.42 | -0.52 | -0.46 | -0.35 | 0.51 | -0.20 | -0.13 | -0.11 | -0.07 | -0.16 | -0.18 |
| Free Cash Flow | (44.95M) | (43.48M) | (47.24M) | (39.64M) | (40.83M) | 41.70M | (14.61M) | (7.32M) | (6.79M) | (17.31M) | (12.81M) | (16.70M) |
| FCF / Share | -0.45 | -0.44 | -0.48 | -0.40 | -0.42 | 0.43 | -0.15 | -0.08 | -0.07 | -0.18 | -0.13 | -0.18 |
| Operating CF | (44.95M) | (43.48M) | (47.05M) | (39.59M) | (40.74M) | 42.00M | (14.47M) | (7.28M) | (6.71M) | (17.41M) | (12.76M) | (16.67M) |
| Total Assets | 287.57M | 327.65M | 372.80M | 313.47M | 327.32M | 351.15M | 217.60M | 221.97M | 227.58M | 233.19M | 248.56M | 258.75M |
| Total Debt | 97.11M | 96.96M | 1.53M | 1.66M | 73,000 | 42,000 | 102,000 | 160,000 | 217,000 | 274,000 | 327,000 | 379,000 |
| Cash & Equiv | 24.32M | 41.32M | 59.56M | 51.54M | 39.86M | 50.82M | 39.66M | 36.63M | 56.01M | 70.97M | 60.53M | 119.02M |
| Book Value | 61.31M | 114.26M | 147.66M | 192.32M | 228.97M | 256.80M | 200.98M | 215.24M | 223.87M | 230.76M | 237.28M | 248.55M |
| Return on Equity | -0.99 | -0.36 | -0.35 | -0.23 | -0.15 | 0.19 | -0.10 | -0.06 | -0.05 | -0.03 | -0.06 | -0.07 |
SPRY News
ARS Pharmaceuticals: Still A Buy As Neffy Access Improves
ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript
ARS Pharmaceuticals Q1 Earnings Call Highlights
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
Earnings Preview: ARS Pharmaceuticals, Inc. (SPRY) Q1 Earnings Expected to Decline
ARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock?